Serum angiopoietin-like protein 3 concentrations in rheumatic diseases

European Journal of Dermatology

Volumn 22, Issue 4, 2012, Pages 500-504

  Hayashi, Yasuyo ^a   Jinnin, Masatoshi ^a   Makino, Takamitsu ^a   Kajihara, Ikko ^a   Makino, Katsunari ^a   Honda, Noritoshi ^a   Nakayama, Wakana ^a   Inoue, Kuniko ^a   Fukushima, Satoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Angiopoietin like protein 3; Dermatomyositis; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; MYOGLOBIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PATHOGENESIS; POLYMYOSITIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UPREGULATION;

ANGIOPOIETINS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; RHEUMATIC DISEASES;

EID: 84865355638     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1774     Document Type: Article

References (34)

1. Soltész P, Kerekes G, Dér H, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011; 10: 416-25.
2. Pattanaik D, Brown M, Postlethwaite AE. Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res 2011; 4: 105-25.
3. Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-53.
4. Dalakas MC. Review: An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011; 37: 226-42.
5. Szekanecz Z, Koch AE Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008; 10: 224.
6. Torley HI, Madhok R, Capell HA, et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991; 50: 800-4.
7. Lambova SN, Kuzmanova SI. Raynaud's phenomenon in common rheumatic diseases. Folia Med (Plovdiv) 2006; 48: 22-8.
8. Tunc SE, Ertam I, Pirildar T, et al. Nail changes in connective tissue diseases: do nail changes provide clues for the diagnosis? J Eur Acad Dermatol Venereol 2007; 21: 497-503.
9. Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010; 6: 578-87.
10. Kersten S. Regulation of lipid metabolism via angiopoietin-like proteins. Biochem Soc Trans 2005; 33: 1059-62.
11. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002; 277: 33742-8.
12. Legry V, Bokor S, Cottel D, et al. Associations between common genetic polymorphisms in angiopoietin-like proteins 3 and 4 and lipid metabolism and adiposity in European adolescents and adults. J Clin Endocrinol Metab 2009; 94: 5070-7.
13. Camenisch G, Pisabarro MT, Sherman D, et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin _V_3 and induces blood vessel formation in vivo. J Biol Chem 2002: 277: 17281-90.
14. Zhang CC, Kaba M, Ge G, et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 2006; 12: 240-5.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
17. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
18. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
20. Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 1999; 11: 475-82.
21. Ihn H, Sato S, Tamaki T, et al. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992; 284: 391-5.
22. Guo W, Che Z, Xu A, Zhou Z. Angiopoietin-like protein 3 and adiponectin levels in patients with metabolic syndrome. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010; 35: 203-8.
23. Arakawa H, Jinnin M, Muchemwa FC, et al. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol 2011; 20: 764-6.
24. Ogata A, Endo M, Aoi J, et al. The role of angiopoietin-like protein 2 in pathogenesis of dermatomyositis. Biochem Biophys Res ommun. 2012 in Press.
25. Stejskal D, Karpísek M, Humenanská V, et al. Angiopoietin-like protein 3: development, analytical characterization, and clinical testing of a new ELISA. Gen Physiol Biophys 2007; 26: 230-3.
26. Yilmaz Y, Ulukaya E, Atug O, Dolar E. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol 2009; 21: 1247-51.
27. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109-16.
28. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006; 37: 190-7.
29. Masui Y, Asano Y, Shibata S, et al. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2011 in Press.
30. Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M. The role of adiponectin in human vascular physiology. Int J Cardiol. 2011 in press.
31. Ricci R, Bevilacqua F. The potential role of leptin and adiponectin in obesity: A comparative review. Vet J. 2011 in press.
32. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
33. Legry V, Bokor S, Cottel D, et al. Associations between common genetic polymorphisms in angiopoietin-like proteins 3 and 4 and lipid metabolism and adiposity in European adolescents and adults. J Clin Endocrinol Metab 2009; 94: 5070-7.
34. Járomi L, Csöngei V, Polgár N, et al. Triglyceride level-influencing functional variants of the ANGPTL3, CILP2, and TRIB1 loci in ischemic stroke. Neuromolecular Med 2011; 13: 179-86.